Genentech, a member of the Roche Group, is a global biotechnology leader focusing strongly on oncology and hematology, and develops innovative biologic and targeted therapies aimed at improving outcomes for Veterans with cancer and blood disorders. Its portfolio includes several foundational therapies that have transformed treatment paradigms across multiple tumor types and hematologic malignancies.

In oncology, Genentech offers a broad range of targeted therapies and immunotherapies. Key products include Herceptin® (trastuzumab) and Perjeta® (pertuzumab) for HER2-positive breast cancer, as well as Phesgo® (pertuzumab, trastuzumab, and hyaluronidase-zzxf), a fixed-dose subcutaneous combination that enables more convenient administration of HER2-targeted therapy. Avastin® (bevacizumab) remains an important therapy across multiple solid tumors, while Tecentriq® (atezolizumab), an immune checkpoint inhibitor, is used in several cancers including lung and liver cancer. Additional targeted therapies such as Alecensa® (alectinib) for ALK-positive non-small cell lung cancer further highlight Genentech’s commitment to biomarker-driven treatment and precision medicine.

In hematology, Genentech has developed a significant portfolio addressing B-cell malignancies and other blood disorders. Important therapies include Rituxan® (rituximab), a pioneering anti-CD20 monoclonal antibody used across multiple lymphomas and leukemias; Gazyva® (obinutuzumab) for chronic lymphocytic leukemia and follicular lymphoma and Polivy® (polatuzumab vedotin), an antibody-drug conjugate for diffuse large B-cell lymphoma. Newer bispecific antibodies such as Lunsumio® (mosunetuzumab) and Columvi® (glofitamab) further expand treatment options for relapsed or refractory lymphomas.

Genentech’s oncology and hematology portfolio reflects a continued commitment to advancing precision medicine and improving outcomes for Veterans living with cancer and hematologic diseases through innovative science, collaboration, and clinical research partnerships.